What Scytera Treats: Main Uses and Benefits

Scytera (Coal Tar topical foam) is commonly used to help manage the symptomatic manifestations of chronic skin conditions such as psoriasis, seborrheic dermatitis, and select forms of chronic eczema. The active ingredient is applied across domains where additional symptomatic support is needed to address chronic inflammatory or irritative states.

Symptom Relief and Therapeutic Benefits

This medication is relevant for managing conditions characterized by periods of heightened symptoms, primarily focusing on excessive skin scaling, flaking, and persistent pruritus (itching). It may assist with managing symptoms related to excessive skin cell growth that leads to thickened plaques.

“It is used for managing symptoms of scaling and flaking and provides supportive relief that helps patients cope more steadily with difficult episodes.”

The specialized foam formulation is often used in clinical settings that involve acute or unstable symptom patterns, particularly for managing conditions affecting the scalp or other areas with hair. Its use assists with maintaining functional stability and contributes to improved day-to-day comfort during symptomatic periods.

Quick Fact

Regulatory References

1. NIH DailyMed Labeling

Who Can and Cannot Use Scytera? (Official Regulatory Information)

Official regulatory documents define eligibility for Scytera (Coal Tar Topical Foam) by establishing specific contraindications and use restrictions based on patient population and pre-existing conditions.

Contraindicated and Restricted Populations

Age-Specific Eligibility and Data Limitations

The established safety and efficacy profile for Scytera is primarily based on adult patients. Its use in other age groups is limited by insufficient data:

• Infants: Use is not recommended unless explicitly directed by a healthcare professional.
• Children (General): Safety and efficacy have not been established in the pediatric population.
• Older Adults (Geriatric): No specific information comparing use in this group to younger adults is documented in the official labeling.

Pregnancy and Lactation Status

Use during pregnancy is conditional and should only be considered if the therapeutic benefit justifies the potential risk, with some regulatory sources advising avoidance during the first trimester. For lactating individuals, safe use has not been established, and careful measures, such as washing the product off the breast area, are advised to prevent accidental infant ingestion.

Interactions with other medicines and products

Documented Pharmacodynamic Interactions

The official regulatory interaction profile for Scytera is defined primarily by the potential for an additive photosensitizing effect when combined with other substances. This is a pharmacodynamic interaction involving certain prescription medicinal products classified as Photosensitizing Agents, including specific drugs used in therapies such as ultraviolet radiation treatment for psoriasis. Co-administration with these agents, or exposure to external ultraviolet ( UV) radiation sources, may result in an increased tendency for severe skin sensitivity and reaction.

Interaction-Related Restrictions and Timing Rules

Due to this documented light-sensitivity interaction, mandatory cautions are noted in the regulatory labeling regarding external factors. The official documents specify a timing constraint advising caution in exposing treated skin to natural sunlight or artificial UV rays, such as those from sunlamps or tanning beds. This increased skin sensitivity to light may persist for a defined period of up to 24 hours following the product's application.

Pharmacokinetic and Substance Interactions

No formal pharmacokinetic interactions are documented in the official prescribing information. Specifically, there are no reported interactions involving CYP enzymes, drug transporters, or co-administered substances that would officially alter the systemic exposure of Scytera. Furthermore, no specific interactions with food, alcohol, or herbal products are formally reported in regulatory sources.

Scytera, containing coal tar, exerts its action primarily at the level of the epidermal cell and underlying dermal microcirculation. The precise mechanism is complex and multifactorial, but it is characterized by several key biological interactions. The active components are thought to penetrate the stratum corneum, leading to a suppression of deoxyribonucleic acid (DNA) synthesis within hyperproliferative keratinocytes. This results in an inhibition of excessive epidermal cell multiplication and the subsequent abnormal differentiation of these cells, which is a characteristic feature of the target tissue state. Furthermore, Scytera exhibits modulation of various local inflammatory pathways. It possesses anti-inflammatory properties by influencing eicosanoid metabolism and potentially suppressing the activity of pro-inflammatory cytokines and chemokines within the dermis. This cascade dampens the localized inflammatory response. The compound also displays mild antimicrobial activity, which contributes to its overall physiological consequence of normalizing cell turnover and mitigating dermal inflammatory signals.

How to Use Scytera: Official Administration Guidelines

Scytera is an emollient foam containing 2% Coal Tar that is strictly intended for topical application to the affected skin areas and the scalp. This product is for external use only and follows a standardized regimen based on regulatory guidance.

Dosing and Frequency

Procedural Administration

Proper use of the foam formulation requires specific handling steps to ensure correct delivery of the active ingredient. The container must be shaken well immediately before each use. To dispense the foam correctly, the can must be inverted; dispensing it upright will cause the loss of the propellant.

After dispensing, the foam is applied to the affected area and rubbed in until it disappears. Official instructions mandate avoiding contact with sensitive areas such as the eyes, mouth, nose, rectum, and genital/groin area during application.

Use in Specific Populations

Use in pediatric patients must be specifically determined and supervised by a physician. Official labeling typically does not specify dosage adjustments for older adults or individuals with renal or hepatic impairment due to the drug's topical route of administration.

Research Evidence / Overview of Studies for Scytera (Coal Tar Topical Foam)

Evidence for Use in Chronic Plaque Psoriasis

Research on the active ingredient, Coal Tar, in research exploring signs and symptoms of chronic plaque psoriasis has been conducted through various clinical trial structures, including Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies primarily focused on adults experiencing mild to moderate forms of the condition. Researchers monitored specific clinical outcomes, such as measurements related to scaling, redness (erythema), and thickness (induration) of skin lesions, and also tracked subjective outcomes like itching (pruritus). These studies were used in research exploring how symptoms change over time and were relevant in trials assessing short-term or episodic symptom patterns.

Findings describe patterns observed in the studies, reporting the measured outcomes on the specific clinical assessment scales used by investigators over a short time interval. However, the evidence base for the specific topical foam formulation is often drawn from the broader research landscape of the active ingredient, meaning research that is exclusive to the foam vehicle is less common.

Evidence for Use in Seborrheic Dermatitis

The active ingredient of Scytera was studied in research settings focused on the signs of seborrheic dermatitis, which is a condition involving periods of heightened symptoms, particularly excessive flaking and itching. Research examined the component in various topical forms, including solutions and medicated shampoos, and was evaluated in comparative studies against non-medicated vehicles or other standard topical agents. The outcomes studied focused on monitoring specific disease characteristics, such as measuring the outcomes related to physical discomfort, like scaling/dandruff and the severity of pruritus in adults.

Studies report the monitoring of symptoms, documenting the outcomes measured for scaling and itching over short-term follow-up periods. The findings varied across different formulations.

Duration of Study and Long-Term Follow-up

The typical duration for clinical trials relevant to this medicine is short-term, often spanning just a few weeks (e.g., 2 to 12 weeks), which provides insight into symptom patterns during the short-term period. Follow-up durations were limited in many of the key studies. Consequently, long-term effects are not fully established for the foam formulation. There is limited information for long-term outcomes regarding the patterns of sustained stability or the potential for symptom recurrence when the foam is used continuously for prolonged periods. The durability of the response beyond these short intervals remains an area of uncertainty.

Key Evidence Gaps and Areas of Uncertainty

A primary limitation is that comparative evidence is lacking for the specific foam formulation against the inert vehicle or placebo in the same large-scale trials used for newer drugs. Many findings are derived from the broader, historical evidence base of the active ingredient, where the findings varied across studies due to differences in formulation, concentration, and patient inclusion criteria. The short follow-up durations mean that understanding the long-term patterns related to outcomes reflecting daily functioning or activity level remains an area requiring further study.

Key Studies & References Coal Tar Topical Foam - NIH DailyMed Labeling

Common questions about Scytera (FAQ)

Q: Why are there so many warnings listed on the Scytera leaflet?

Official documentation includes warnings to inform users about known effects associated with the active ingredient. These reflect common local effects like transient stinging, burning, and skin irritation. The leaflets also emphasize the risk of increased photosensitivity (sensitivity to light), which may persist for up to 24 hours after applying the product.

Q: How quickly should a person expect to notice any difference after starting Scytera?

Research examining the active ingredient typically involved short-term clinical trial structures, with follow-up periods often spanning a few weeks, such as 2 to 12 weeks. This data provides insight into how symptoms responded to the treatment during the initial phase of use.

Q: What information do official documents provide for an accidental overdose?

Scytera is strictly for external use only as a topical foam. If the product is accidentally swallowed or used in an amount significantly greater than directed, official labeling notes that contacting a Poison Control Center or seeking immediate medical attention is a recommended step.

Q: Can I stop taking Scytera once my symptoms improve, or is it a long-term treatment?

Official guidance indicates that Scytera use should be intermittent and is not intended for prolonged continuous periods. The frequency of application is typically decreased once symptomatic control is achieved.

Q: Is Scytera affected by grapefruit or grapefruit juice?

According to the official prescribing information, there are no specific interactions formally reported with food, alcohol, or common herbal products.

Q: Can Scytera be split or crushed to make it easier to swallow?

The product is not an oral medication. Scytera is formulated as a topical emollient foam and is only intended for application to the skin and scalp. It is not designed to be swallowed, split, or crushed.

Q: What is the purpose of the boxed warning, if Scytera has one?

Official labeling for products containing coal tar may include warnings related to the chemical composition. For instance, the labeling may contain the California Proposition 65 warning, which states that coal tar contains chemicals known to the State of California to cause cancer.

Q: Is Scytera considered a new kind of medicine, or has it been around for a while?

The active ingredient in Scytera, Coal Tar, is described in regulatory documents as a centuries-old dermatological remedy. It is a derived substance with widely recognized clinical utility in managing certain skin conditions.

Q: What do official documents say about Scytera and kidney issues?

Due to Scytera’s topical route of administration (applied to the skin), official labeling typically does not specify dosage adjustments for individuals with renal impairment (kidney issues).

Q: What is the risk of having a serious allergic reaction to Scytera?

Official documents describe that serious adverse reactions are documented, and they typically relate to signs of severe allergic reaction or severe, persistent local irritation. Official guidance indicates that such reactions may necessitate stopping treatment.

Q: Does taking Scytera require regular blood tests or monitoring?

The regulatory guidance and administration instructions focus exclusively on the steps for topical application. Official information does not mention the need for routine systemic monitoring, such as blood tests.

Q: If I miss a dose of Scytera, what are the general guidelines?

General documentation for topical coal tar products outlines steps to consider regarding missed applications. This often suggests application upon remembering unless the next dose is due, at which point the missed dose may be skipped, and the regular schedule is followed.

Q: Does Scytera interact with birth control pills?

No formal pharmacokinetic interactions are documented in the official prescribing information. This suggests that the product does not officially alter the systemic exposure of co-administered substances, such as birth control pills.

Q: Can I take Scytera if I am also being treated for a high cholesterol condition?

Official documentation does not report any formal pharmacokinetic interactions. This indicates the product does not officially alter the systemic exposure of co-administered medicines, including those used to treat high cholesterol.

Q: What is the difference between the brand name Scytera and its generic name?

Scytera is the brand name given to the topical foam product. Its active ingredient is the generic substance Coal Tar, which is classified as a complex mixture rather than a single-entity drug.

Q: Are there any rare but serious risks associated with long-term Scytera use?

Long-term use is associated with the development of acne-like eruptions at the application site. Animal studies have also shown that coal tar may increase the chance of skin cancer, and related warnings are noted on the official labeling.

How to Store and Dispose of Scytera Topical Foam

Scytera (coal tar topical foam) must be stored at controlled room temperature, specifically between 68°F and 77°F (20°C and 25°C). The container must be kept tightly closed and stored away from heat, open flame, and direct sunlight. The product is a pressurized, flammable aerosol and must not be exposed to temperatures exceeding 120°F (49°C).

Keep the medicine out of reach of children.

For disposal, the container must not be punctured or thrown into a fire or incinerator. Dispose of unused product in accordance with local laws and regulations for pharmaceutical waste.